Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly FCF Margin of 84877.3% for Q1 2026, up 4392686.0% year-over-year from N/an in Q1 2025, and down 366.94% quarter-over-quarter from 18177.27% in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's FCF Margin history runs 14 years deep, the most recent figure standing at 84877.3% for Q1 2026.
- In Q1 2026, FCF Margin rose 4392686.0% year-over-year to 84877.3%; the TTM figure through Mar 2026 stood at 428.42% (up 9240139.0% YoY), while the FY2025 annual figure was 390.81%, up 7670522.0% from the prior year.
- FCF Margin for Q1 2026 stood at 84877.3%, down from 18177.27% in the prior quarter.
- The five-year high for FCF Margin was 120.08% in Q3 2025, with the low at 128804.17% in Q1 2025.
- The 5-year median for FCF Margin is 62809.72% (2024), against an average of 54443.15%.
- Peak annual rise in FCF Margin reached 8383106 bps in 2025, while the deepest fall reached 6599444 bps in 2025.
- Viridian Therapeutics, Inc.\DE's FCF Margin stood at 32243.81% in 2022, then plunged by 64 bps to 52844.44% in 2023, then sank by 93 bps to 102008.33% in 2024, then soared by 82 bps to 18177.27% in 2025, then slumped by 367 bps to 84877.3% in 2026.
- Business Quant data shows VRDN's FCF Margin at 84877.3% in Q1 2026, 18177.27% in Q4 2025, and 120.08% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | -37,545.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37,545.77% |
| Mar 31, 2026 | -84,877.30% |
| Dec 31, 2025 | -18,177.27% |
| Sep 30, 2025 | -120.08% |
| Jun 30, 2025 | -100,553.33% |
| Mar 31, 2025 | -128,804.17% |
| Dec 31, 2024 | -102,008.33% |
| Sep 30, 2024 | -79,068.60% |
| Jun 30, 2024 | -64,113.89% |
| Mar 31, 2024 | -62,809.72% |
| Dec 31, 2023 | -52,844.44% |
| Sep 30, 2023 | -54,704.17% |
| Jun 30, 2023 | -63,020.83% |
| Mar 31, 2023 | -63,528.57% |
| Dec 31, 2022 | -32,640.95% |
| Sep 30, 2022 | -1,737.49% |
| Jun 30, 2022 | -7,178.91% |
| Mar 31, 2022 | -9,824.54% |
| Dec 31, 2021 | -7,765.89% |
| Sep 30, 2021 | -5,774.04% |